drugset / Trial / NCT06978244
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
RandomizedSingle-groupDouble-blindTreatment
Summary
Single-Center, Phase 1 study to assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
Timeline
- Start
- 2025-07-29
- Primary completion
- 2026-11
- Completion
- 2026-11
Outcome
Met primary endpoint
release “BL1332 0.30% ophthalmic solution in a capsaicin-induced ocular pain challenge model in healthy adult participants. The study met its primary endpoint” bausch.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BL1332 | Unknown | 0.06 % | Topical |
| Subject | BL1332 | Unknown | 0.15 % | Topical |
| Subject | BL1332 | Unknown | 0.3 % | Topical |
Indications
No indication recorded.